Skip to main content
Show — Main navigation Hide — Main navigation
  • Home
  • About
    • The Chair
    • Inquiry Team
    • Expert Groups
    • Inquiry Intermediaries
    • Core Participants
    • Legal Representatives
    • Financial Reports
  • Approach
    • Terms of reference
    • List of Issues
    • Statements of approach
    • Inquiry Principles
  • News
    • News
    • Newsletter Archive
  • Reports
    • Compensation Framework Study
    • First Interim Report
    • Second Interim Report
    • The Inquiry Report
  • Publication Day
  • Evidence
    • Evidence
    • Hearings Archive
  • Compensation
  • Support
    • Confidential Psychological Support
    • Interim Payments
    • Support Groups
    • Get in touch
    • Infected Blood Support Schemes
    • Treatment and aftercare
    • Medical Evidence
    • Expenses Guidance
Accessibility Tool
  • Zoom in
  • Zoom out
  • Reset
  • Contrast
  • Accessibility tool
Get in touch

Quick Exit

Dr Harris in a letter to Dr Colvin stated that each donation was now screened for HTLV-3 but that they recognised old material may be in centres and any decision to give patients information about this potentially distressing information rested with Dr Colvin as the unit director.

  • Read more about Dr Harris in a letter to Dr Colvin stated that each donation was now screened for HTLV-3 but that they recognised old material may be in centres and any decision to give patients information about this potentially distressing information rested with Dr Colvin as the unit director.

In a letter to Dr Rotblat, Dr Christie reported the second case of seroconversion following the use of heat-treated Armour Factorate.

  • Read more about In a letter to Dr Rotblat, Dr Christie reported the second case of seroconversion following the use of heat-treated Armour Factorate.

Armour's Factorate was removed from the market and two of its product licenses relinquished following consultation with the DHSS after two seroconversion cases of AIDS from heat treated Factorate.

  • Read more about Armour's Factorate was removed from the market and two of its product licenses relinquished following consultation with the DHSS after two seroconversion cases of AIDS from heat treated Factorate.

Dr Jeffreys Chief Medical Officer said further to the call with Dr Rotblatt they would need to visit the DHSS the next day before the weekend and that Armour would probably be "no doubt looking at voluntarily withdrawing the product on Monday".

  • Read more about Dr Jeffreys Chief Medical Officer said further to the call with Dr Rotblatt they would need to visit the DHSS the next day before the weekend and that Armour would probably be "no doubt looking at voluntarily withdrawing the product on Monday".

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat treated product Robert Christie said Dr Harris had reported the findings in broad outline to DHSS and promised to supply more information following a written report from Dr Hill

  • Read more about In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat treated product Robert Christie said Dr Harris had reported the findings in broad outline to DHSS and promised to supply more information following a written report from Dr Hill

In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat-treated product Robert Christie said Dr Harris had reported the findings in broad outline to the DHSS and promised to supply more information following a written report from Dr Hill. Robert Christie said he agreed that the incident should be reported to the DHSS and a publication describing Dr Hill's experience prepared.

  • Read more about In a memo regarding the seroconversion of two children with haemophilia who had received Armour heat-treated product Robert Christie said Dr Harris had reported the findings in broad outline to the DHSS and promised to supply more information following a written report from Dr Hill. Robert Christie said he agreed that the incident should be reported to the DHSS and a publication describing Dr Hill's experience prepared.

In a memo Christopher Bishop advised colleagues on responses to be used with regards to queries about them reviewing their heat treatment procedure and said they had a considerable quantity of existing material and they wouldn't want people to hold off ordering until the new product came through.

  • Read more about In a memo Christopher Bishop advised colleagues on responses to be used with regards to queries about them reviewing their heat treatment procedure and said they had a considerable quantity of existing material and they wouldn't want people to hold off ordering until the new product came through.

In response to the media response on AIDS fears prompting recall of blood products Christopher Bishop said that Armour should treat media articles with the contempt they deserved and that they could not make a statement on reviewing the current heat process because they couldn't defend existing treatment and immediately introduce a new one.

  • Read more about In response to the media response on AIDS fears prompting recall of blood products Christopher Bishop said that Armour should treat media articles with the contempt they deserved and that they could not make a statement on reviewing the current heat process because they couldn't defend existing treatment and immediately introduce a new one.

In a letter to blood banks directors and haemophilia treatment centre coordinators Armour recommended that lots of HT Factorate concentrates derived from non-tested plasma should not be used and that they would arrange for centres to exchange any inventory of product manufactured from untested plasma at no cost to the centres.

  • Read more about In a letter to blood banks directors and haemophilia treatment centre coordinators Armour recommended that lots of HT Factorate concentrates derived from non-tested plasma should not be used and that they would arrange for centres to exchange any inventory of product manufactured from untested plasma at no cost to the centres.

In a memo, Dr Harris discussed his conversation with Dr Jones who told him that he did not wish to receive replacement material since it was his belief that their (Armour's) material was less safe in the hepatitis risk area. Dr Jones asked for the letter and this call to be confidential as he had recently had "his wrists slapped for public statements".

  • Read more about In a memo, Dr Harris discussed his conversation with Dr Jones who told him that he did not wish to receive replacement material since it was his belief that their (Armour's) material was less safe in the hepatitis risk area. Dr Jones asked for the letter and this call to be confidential as he had recently had "his wrists slapped for public statements".

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 226
  • Page 227
  • Page 228
  • Page 229
  • Current page 230
  • Page 231
  • Page 232
  • Page 233
  • Page 234
  • …
  • Next page Next ›
  • Last page Last »
Subscribe to

Inquiry

  • Home
  • About
  • Approach
  • Participate
  • News
  • Evidence
  • Support
  • Get in touch

Legal

  • Terms & Conditions
  • Cookies notice
  • Privacy Notice
  • Accessibility tool

Address

Infected Blood Inquiry
5th Floor
Aldwych House
71-91 Aldwych
London
WC2B 4HN
 
Images of individuals on the website are used with the agreement of those featured or are stock images.

Follow us

© Crown copyright. Licensed under the Open Government Licence v3.0 except where otherwise stated.